BioLineRx (NASDAQ:BLRX) Upgraded at StockNews.com

BioLineRx (NASDAQ:BLRX) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday.

Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Wednesday, April 17th.

BioLineRx Stock Down 3.7 %

Shares of NASDAQ:BLRX opened at $0.61 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47. The firm has a market capitalization of $49.00 million, a PE ratio of -0.68 and a beta of 1.38. The firm’s 50-day moving average is $1.03 and its two-hundred day moving average is $1.31. BioLineRx has a 1 year low of $0.59 and a 1 year high of $2.53.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. Analysts predict that BioLineRx will post -1.03 EPS for the current year.

Hedge Funds Weigh In On BioLineRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. boosted its holdings in BioLineRx by 88.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 10,000 shares in the last quarter. NorthRock Partners LLC acquired a new position in BioLineRx in the fourth quarter valued at approximately $27,000. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in BioLineRx in the third quarter valued at approximately $46,000. Rathbones Group PLC acquired a new position in BioLineRx in the third quarter valued at approximately $72,000. Finally, Values First Advisors Inc. acquired a new stake in shares of BioLineRx in the third quarter valued at approximately $88,000. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.